FDA clears Novartis' hypertension medicine Tekturna HCT

07/21/2009 | Reuters

Novartis secured FDA clearance to market its Tekturna HCT combination treatment for patients with high blood pressure who do not respond to a standalone therapy. The medicine contains the diuretic hydrochlorothiazide, a common regimen for hypertension.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA